Hyperinsulinism – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:17:40 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Hyperinsulinism – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Ersodetug for Patients with Uncontrolled Low Blood Sugar Due to Tumor-Related High Insulin Levels https://clinicaltrials.eu/trial/study-on-ersodetug-for-patients-with-uncontrolled-low-blood-sugar-due-to-tumor-related-high-insulin-levels/ Wed, 29 Apr 2026 15:06:09 +0000 https://clinicaltrials.eu/trial/study-on-ersodetug-for-patients-with-uncontrolled-low-blood-sugar-due-to-tumor-related-high-insulin-levels/ This study investigates tumor-associated hyperinsulinism (tumorHI), a condition where tumors cause excessive insulin production leading to low blood sugar levels (hypoglycemia). The condition can result from islet-cell tumors (insulinomas/proinsulinomas) or non-islet cell tumors. The purpose is to evaluate how effective and safe the medication ersodetug is when added to standard treatments for people whose hypoglycemia is not adequately controlled by current therapies.

The study is designed as a phase 3, randomized, double-blind trial comparing ersodetug to a placebo. Participants in the study have tumors that cause too much insulin to be released, resulting in dangerously low blood sugar levels that haven’t responded well to typical treatments. These individuals experience multiple episodes of severe hypoglycemia weekly, sometimes requiring assistance from others due to altered mental or physical status.

During the study, participants will receive either ersodetug or placebo while continuing their standard care treatments. Researchers will monitor how frequently participants experience low blood sugar events and how severe these events are. The study will track changes in hypoglycemic episodes and measure blood glucose levels through regular testing to determine if ersodetug helps reduce the frequency and severity of low blood sugar episodes.

]]> Study on the Safety and Effects of Efpegerglucagon in Children Aged 2 and Older with Congenital Hyperinsulinism https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-efpegerglucagon-in-children-aged-2-and-older-with-congenital-hyperinsulinism/ Wed, 29 Apr 2026 14:27:35 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-efpegerglucagon-in-children-aged-2-and-older-with-congenital-hyperinsulinism/ This clinical trial is focused on studying a condition known as Congenital Hyperinsulinism (CHI). This is a rare condition where the body produces too much insulin, leading to low blood sugar levels. The trial will test a new treatment called HM15136, which is a solution for injection. The purpose of the study is to evaluate the safety and how well the body tolerates this new treatment, as well as to understand how the drug behaves in the body over time.

Participants in the study will receive the HM15136 treatment for a period of 8 weeks. During this time, researchers will monitor the participants to see how their bodies respond to the treatment. This includes checking for any side effects and measuring how the drug is processed in the body. The study will also look at how the treatment affects the frequency of low blood sugar events in participants.

The study is open-label, meaning both the researchers and participants will know that HM15136 is being administered. Participants will receive the treatment through injections under the skin. The study aims to provide valuable information on the potential benefits and risks of HM15136 for children with Congenital Hyperinsulinism, which could lead to better management of this condition in the future.

]]> Study on RZ358 for Treating Congenital Hyperinsulinism in Patients https://clinicaltrials.eu/trial/study-on-rz358-for-treating-congenital-hyperinsulinism-in-patients/ Wed, 29 Apr 2026 14:25:38 +0000 https://clinicaltrials.eu/trial/study-on-rz358-for-treating-congenital-hyperinsulinism-in-patients/ This clinical trial is focused on studying a condition known as , which causes low blood sugar levels, or , due to excessive insulin production. The trial will evaluate a treatment called , which is a type of medication known as a . This medication is designed to target and block the insulin receptor, potentially helping to manage blood sugar levels in patients with this condition. The study will also include a group for comparison.

The purpose of the study is to assess how effective and safe is in treating patients with . Participants in the study will receive the treatment through an , which means the medication will be administered directly into a vein. The study will last for a period of 24 weeks, during which the frequency of events will be monitored. This will help determine if can reduce the number of low blood sugar episodes experienced by patients.

Throughout the study, participants will be closely monitored for any side effects or changes in their health. This will include regular check-ups, blood tests, and other assessments to ensure the safety and well-being of all participants. The study aims to provide valuable information on the potential benefits of for individuals with and contribute to the development of new treatment options for this condition.

]]>